MRSA bacteremia
Staphylococcus aureus bacteremia (SAB), particularly when caused by methicillin-resistant strains (MRSA), remains one of the deadliest common bloodstream infections, with 30-day mortality of roughly 20-30% even with optimal antibiotics. Standard therapy is hampered by metastatic seeding (endocarditis, vertebral osteomyelitis, prosthetic devices), persistent/recurrent bacteremia, biofilm on catheters and implants, and rising resistance and tolerance to vancomycin and daptomycin. Lytic bacteriophages are well suited as an adjunct because they self-amplify at the site of infection, kill by a mechanism entirely orthogonal to antibiotics (so they retain activity against multidrug-resistant and antibiotic-tolerant cells), penetrate biofilm and target persisters, and can be delivered intravenously as a defined cocktail to broaden host range and suppress resistance. This makes phage-antibiotic combination therapy an attractive strategy precisely for the complicated, relapsing SAB that antibiotics alone fail to clear.
How phages act here
Mechanism
Anti-staphylococcal therapeutic phages used in SAB are obligately lytic Myoviridae (Herelleviridae) related to Staphylococcus phage K; they adsorb to wall teichoic acid/cell-wall receptors, inject their genome, hijack the host, and lyse the cell, releasing progeny that propagate the kill in an auto-dosing fashion. Host range is strain-specific, so therapeutic products are formulated as fixed cocktails of 3 phages (e.g., AB-SA01 and AP-SA02) to cover the great majority of clinical isolates and to raise the genetic barrier to resistance; AB-SA01's three myoviruses lysed ~94.5% of 401 clinical S. aureus isolates in vitro. Key advantages against SAB are biofilm penetration and killing of metabolically dormant persisters that tolerate antibiotics, and phage-antibiotic synergy (PAS), where sub-lethal beta-lactams or other agents enhance phage replication/lysis and the two together suppress emergence of resistance. A notable mechanistic observation from the AP-SA02 program is intra-cocktail adaptation: a minor defined phage variant (~2% of the product) can expand to dominance when challenged with a given patient's isolate, effectively self-tuning to the infecting strain. Engineered and CRISPR-based anti-staphylococcal phages (e.g., sequence-specific antimicrobials and locked/host-range-engineered phages) are an active preclinical frontier but are not yet the basis of the bacteremia trials.
Where it stands
Current evidence
Evidence has progressed from compassionate-use case reports to a positive randomized controlled trial. The foundational human safety data came from the Westmead (Australia) single-arm trial (Petrovic Fabijan et al., Nature Microbiology 2020), in which IV AB-SA01 was given twice daily for up to 14 days to 13 critically ill patients with severe S. aureus infection including bacteremia, endocarditis and septic shock — no adverse reactions attributable to phage, no in vivo resistance. The pivotal advance is Armata Pharmaceuticals' diSArm trial (NCT05184764), a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study of IV AP-SA02 plus best available antibiotic therapy (BAT) vs placebo plus BAT in complicated S. aureus bacteremia. In the Phase 2a portion (42 patients dosed: 29 AP-SA02, 13 placebo; ~38% MRSA in both arms), presented as a late-breaker by Dr. Loren Miller at IDWeek 2025 (Oct 22, 2025), the day-12 clinical response was 88% with AP-SA02 vs 58% with placebo (p=0.047), with 0% relapse/non-response on phage vs 25% on placebo, plus trends toward faster resolution and shorter hospitalization and no relapse at 4 weeks. AP-SA02 holds FDA Fast Track designation for MSSA/MRSA bacteremia, and following an end-of-Phase-2 FDA meeting, Armata plans a Phase 3 superiority study (initiation announced for 2026). This is, to date, the first randomized controlled evidence of efficacy for phage therapy in S. aureus bacteremia.
Evidence confidence: medium
The data
Key studies & trials
- Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR; Westmead Bacteriophage Therapy Team. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature Microbiology. 2020;5(3):465-472. ↗
- Lehman SM, Mearns G, Rankin D, Cole RA, Smrekar F, Branston SD, Morales S. Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections (AB-SA01). Viruses. 2019;11(1):88. ↗
- Armata Pharmaceuticals. A Phase 1b/2a Study of the Safety, Tolerability and Efficacy of Intravenous AP-SA02 in Subjects With S. aureus Bacteremia (diSArm). ClinicalTrials.gov Identifier NCT05184764. ↗
- Miller LG, et al. Phase 2a results of AP-SA02, a bacteriophage cocktail, for complicated Staphylococcus aureus bacteremia (diSArm study). Late-breaking oral presentation, IDWeek 2025, Atlanta, October 22, 2025. ↗
Who is working on it
Programs & centers
The possibility
If the Phase 3 diSArm superiority study confirms the 2a signal, IV phage cocktails could become the first new mechanistic class added to the S. aureus bacteremia armamentarium in decades — an auto-dosing biologic that clears antibiotic-tolerant persisters and biofilm on the very devices and heart valves where antibiotics stall. The strain-adaptive behavior seen with AP-SA02 hints at a future of "living" therapeutics that self-tune to each patient's isolate, paired with rapid phage-susceptibility matching from a curated phage bank. Layered with engineered and CRISPR-armed phages on the horizon, phage-antibiotic synergy could turn relapsing MRSA bacteremia from a frequently fatal, recurrence-prone infection into a reliably curable one.